MedPage Today on MSN
Sapien M3 TMVR Easily Beats Expectations in Pivotal Trial
In ENCIRCLE, TMVR was performed in very ill patients with symptomatic mitral valve disease unsuitable for surgery or ...
Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...
Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback